Elisavet Paplomata, MD
As the FDA continues to approve additional biosimilars in the field of oncology, there is increased hope that these agents could reduce financial toxicity and increase global access to life-saving treatments, said Elisavet Paplomata, MD.
Paplomata believes the trastuzumab biosimilar ABP 980 could be the next biosimilar approved. ABP 980 was evaluated in the phase III LILAC study, which compared the biosimilar plus paclitaxel with trastuzumab/paclitaxel. Data showed that in women with HER2-positive early stage disease, 47.8% of patients in the ABP 980 arm and 41.8% in the trastuzumab arm achieved pathological complete response.
... to read the full story